167
Participants
Start Date
July 31, 2004
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Pegylated Interferon alfa 2a
PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
Ribavirin (HIV conifected patients only)
"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
407 Doctors, Darlinghurst
Holdsworth House GP Practice, Darlinghurst
Kirketon Road Centre, Darlinghurst
St Vincent's Hospital, Darlinghurst
Royal Prince Alfred Hospital, Camperdown
Westmead Hospital, Westmead
John Hunter Hospital, Newcastle
Nepean Hospital, Penrith
The Alfred Hospital, Melbourne
HealthWorks Health Centre, Footscray
Western Hospital, Footscray
Royal Melbourne Hospital, Parkville
St Vincent's Hospital, Fitzroy
Austin Hospital, Heidelburg
Monash Medical Centre, Clayton
Princess Alexandra Hospital, Woolloongabba
Royal Adelaide Hospital, Adelaide
Fremantle Hospital, Fremantle
Lead Sponsor
The University of New South Wales
OTHER
National Institutes of Health (NIH)
NIH
Kirby Institute
OTHER_GOV